No Data
No Data
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright analyst Douglas Tsao maintains $AEON Biopharma(AEON.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 39.0%
Buy Rating Affirmed for AEON Biopharma on Strategic Biosimilar Pathway and Promising Phase 3 Study Prospects
Express News | AEON Biopharma To Undertake Strategic Reprioritization To Advance A Single Pivotal Clinical Development Study In Cervical Dystonia (CD) For Its Lead Candidate, ABP-450 Injection
Express News | AEON Biopharma- Plan to Move Ahead With Head-to-Head Comparison to Botox in Cervical Dystonia Phase 3 Study via 351(K) Pathway Post FDA Meeting in Q3
Express News | AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for Abp-450
Express News | HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $6 Price Target
No Data